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Objectives: Accelerated approval pathways can shorten time to market for thera-
pies treating diseases, particularly those with significant morbidity and mortality 
and few effective alternatives. However, little is known about payers’ reactions to 
submissions based on a Phase 2, single-arm trial. This study aimed to identify mar-
ket access challenges for products with accelerated marketing authorization based 
on this limited data package. MethOds: Oncology products receiving European 
marketing authorization since 2012 based on a Phase 2, single-arm study were 
identified and the associated EPARs and HTA submissions in France, Germany and 
the UK (NICE) reviewed. Results: Six products were identified (Adcetris, Bosulif, 
Erivedge, Iclusig, Imbruvica, and Zydelig); four had orphan designation. No pivotal 
trials included survival as the primary endpoint, none reported HRQL and no com-
parative data were cited in the regulatory packages. Only one product was reviewed 
by NICE (England) and was not recommended (another did not submit). All six G-BA 
(Germany) reviews resulted in either additional benefit not proven, not quantifiable 
(or minor in one subgroup). In France, the ASMR ratings ranged from III to V (mod-
erate, to no improvement compared with existing treatments). Common themes 
identified which could be addressed by additional evidence generation included: (1) 
clarity on the target patient population and unmet need; (2) establishing the cur-
rent standard of care and positioning within the treatment pathway; (3) determin-
ing relative efficacy given the focus on survival benefit and the increasing weight 
of additional value drivers. cOnclusiOns: Although marketing authorization is 
granted, products supported by Phase 2, single-arm trial data face significant HTA 
challenges; payers are being asked to make decisions based on limited data. Some 
evidence gaps can be addressed with additional evidence generated alongside the 
pivotal trial. However, uncertainty about a product’s value may result in poor HTA 
outcomes, and a poor position from which to negotiate price.
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Does BuDget ImPaCt affeCt ReImBuRsemeNt DeCIsIoNs maDe By the 
CaNCeR DRugs fuND IN eNglaND?
Stewart G, Kusel J, Montgomery S
Costello Medical Consulting Ltd, Cambridge, UK
Objectives: The Cancer Drugs Fund (CDF) in England has an annual budget of 
£280 million to fund cancer drugs on the NHS that were not assessed by or were 
rejected by NICE. In 2014, drugs on the CDF were re-assessed based on criteria 
including cost per patient and 16 were removed from the list. Previous analy-
sis on a sub-set of the drugs that were re-assessed indicated that drugs with a 
higher budget impact might be more likely to be rejected by the CDF (presented 
at HTAi 2015). We aimed to expand the analysis to all those re-appraised by 
the CDF, to investigate whether this trends holds when a larger sample size is 
used. MethOds: Using the cost per cycle, cycle length and median duration of 
treatment extracted from the CDF decision summaries, the cost per patient was 
calculated for every drug assessed in 2014. The budget impact of those drugs that 
had previously been reimbursed by the CDF was calculated based on the number of 
notifications that the CDF received in 2014. A point-biserial correlation coefficient 
(rpb) was used to assess whether cost per patient and total budget impact were 
correlated with the CDF reimbursement decision. Results: Investigation of the 
larger sample set confirmed the initial results of the previous analysis and deter-
mined that there was a positive correlation for cancer drugs with a higher cost per 
patient to be included in the CDF (rpb= 0.643); this is most likely due to the superior 
clinical evidence. The budget impact was found to have little influence on the CDF 
reimbursement decision in this larger sample size (rpb= 0.105). cOnclusiOns: 
Although the CDF’s new criteria for reimbursement do involve an evaluation of 
the cost of each drug, it seems that neither the cost per patient nor the overall 
budget impact greatly influences their decisions.
PCN324
PatIeNt RePoRteD outComes (PRo) IN PostPRogRessIoN oNCology: 
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Objectives: To assess the impact of PRO data collected after clinical progression 
(i.e., postprogression) on payer decision making in oncology. MethOds: One-on-
one interviews were conducted with 16 payers and payer advisors from 14 countries 
in 2014. An online assessment was conducted (December 8, 2014, to March 4, 2015) 
with 20 completed surveys (China, France, Germany, Spain, Taiwan, the UK, the US) 
and 7 partially completed surveys (Australia, South Korea, the US) by payers from 
the RTI Health Solutions Global Payer Advisory Panel. Results: PRO data are com-
monly collected during trials; however, collection of PRO data postprogression is 
less common. When asked about the value of collecting PRO data postprogression, 
payers indicated that they consider this particularly important in cancer types with 
relatively long survival and those that involve palliative and/or long-term care. All 
payers in the one-on-one interviews advised collecting postprogression PRO data in 
both the control and comparator arms. Eleven of the 16 respondents in the one-on-
one interviews indicated that it is worthwhile to collect PRO data postprogression 
and that positive PRO data may support continued therapy, even if the tumor is pro-
gressing. Results from the online assessment indicated that payers outside the US 
considered postprogression PRO data more useful than US payers did. When queried 
about specific types of postprogression data, payers generally thought that all types 
of PRO data examined (stability of disease, improvement in health-related quality 
of life, improvement in symptom severity or frequency, improvement in functional 
status, slower rate of functional deterioration compared to control/comparator arm) 
were important to decision making. Payers generally deferred to clinical experts on 
the length and frequency of postprogression PRO data collection. cOnclusiOns: 
PRO data provide compelling evidence even after tumors have progressed clinically 
and may help differentiate products, especially in situations where therapies do not 
provide significant survival benefits.
time gap from TFDA approval to reimbursement on mortality for advanced CRC 
patients. MethOds: The data was form 2 million sampling reimbursement data 
set of Taiwan’s National Health Insurance Research Database (NHIRD) and diseased 
stage was derived from the Taiwan Cancer Registry (TCR) between 2007 and 2011. 
Diseased stage diagnosed for the first time ever of CRC patients was recorded in TCR. 
Patients’ survival data and prescription time of target therapy were derived. Fisher 
exact test was used for the comparisons of frequencies; log rank was used survival 
comparisons; and hazard ratio was derived using both Cox regression with time 
and time independent analysis. Results: 364 staged 4 CRC patients were derived 
and enrolled into the analysis. There were 11 patients diagnosed with CRC before 
the target therapy was approved for reimbursement, whereas 353 were diagnosed 
after. 70 of them were prescribed target therapy during the disease treatment period. 
Median survival years for those who were prescribed target therapy was 2.6 as com-
pared to 1.2 without. There was a statistical significant survival difference between 
target therapy use after the reimbursement approval and non target therapy use 
before approval, HR = 0.073(0.031-0.176), p < 0.0001. The use of target therapy and 
non user was also significant with HR = 0.53(0.369-0.759), p = 0.0005. Multivariate 
Cox regression suggested that the effect of time gap in target therapy reimburse-
ment approval was statistical significant with p = 0.0019 cOnclusiOns: Time gap 
due to reimbursement process influences patient’s mortality. Shortening the time 
gap to reimbursement approval is suggested.
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4+ yeaRs of amNog – ClINICal DRIveRs foR suCCessful DossIeR 
suBmIssIoNs IN oNCology
Dehnen J, Goldhagen K, Petry D
IMS Consulting Group, Muenchen, Germany
Objectives: 135 dossiers have been evaluated by G-BA since AMNOG was intro-
duced. Looking at oncology products, 43 have started into AMNOG process and for 
38 G-BA has finalized its decision. In 32 assessments an additional benefit was 
granted, leading to a success rate of 84% compared to only 36% in non-oncology 
products. Objective of this research is to identify drivers responsible for successful 
benefit assessment outcomes in oncology. MethOds: All oncology assessments 
were analysed to reveal key drivers responsible for positive assessments by IQWiG 
+ G-BA. Next to comparator choice the analysis focused on submitted endpoints, 
where it is evaluated which endpoints contribute most in oncology indications 
to additional benefit. Results: Additional benefit is assessed based on patient 
relevant endpoints (mortality, morbidity, quality of life & safety). More than 55% 
of submitted endpoints fall in the safety category, followed by morbidity (approx. 
30%), mortality (approx. 10%) and quality of life (approx. 5%). OS has shown to be 
the most relevant endpoint, where the G-BA granted additional benefit in 23 out of 
32 dossiers primarily based on OS data. In terms of morbidity, PFS, ORR and “Time 
to Pain Progression” are the top three submitted morbidity endpoints; however, only 
“Time to Pain Progression” led to additional benefit in 2 out of 3 cases and QoL led 
to additional benefit in 4 cases. cOnclusiOns: OS will continue to be the most 
relevant endpoint for IQWiG + G-BA when determining the additional benefit in 
oncology. In the absence of OS, PFS will not help in the overall additional benefit 
decision by G-BA, unless the MNF can justify PFS to be patient relevant according 
to IQWiG methodology. Although QoL is an accepted endpoint by G-BA, due to the 
high methodological standards set by G-BA and IQWiG chances are low that a QoL 
improvement alone will lead to additional benefit.
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Objectives: Many oncological drugs that are being used in the adjuvant setting 
were first submitted for reimbursement in the metastatic stage, with differences 
in incremental cost-effectiveness ratios (ICERs) in both settings having potential 
implications for reimbursement and pricing. The aim of this study is to identify 
a possible trend in the cost-effectiveness for the early/adjuvant and late/meta-
static stages of oncological drugs through review and case study. MethOds: We 
reviewed pairs of cost-effectiveness analyses of the same oncological drug in 
different stages for Scotland and the Netherlands. The case study in this report 
was directed at trastuzumab in the Dutch situation. Using a simplified Markov 
model, the cost-effectiveness in early and late stage of breast cancer was cal-
culated and compared to the findings from the review. Results: Comparable 
studies were found for cetuximab, bortezomib and bosutinib. Treatments in the 
late stage were found to be more expensive per QALY by a factor ranging from 
1.5 to 12. The case study provided a similar result; late stage treatment was more 
expensive by a factor 10. Using, for example, a threshold of € 80,000/QALY, the early 
stage of cetuximab, bosutinib and trastuzumab are deemed cost-effective, while 
their compared late stage is lifted over the threshold and potentially considered 
not cost-effective. cOnclusiOns: ICERs of oncological drugs used in different 
stages are more unfavourable in the late stage than in the early stage. Applying 
a reasonable threshold may result in early stage treatment being deemed cost-
effective while late stage potentially not. Authorities should be aware of this when 
assessing oncological drugs and interpreting the corresponding ICERs, in the situ-
ation where oncological drugs are generally most submitted for reimbursement 
in the late stage initially.
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specific research questions. Results: We identified 327 national or regional general 
oncology registries. Almost each country has databases collecting information on 
diagnosis and survival data, but databases collecting information on treatment and 
response to treatment are rare. Interviews revealed that medical records typically 
collect detailed information on diagnosis, treatment and response, although specific 
details vary per country. cOnclusiOns: The method tested represents a practical 
guide for identifying and assessing available RWE-sources. Patient-registries con-
taining detailed data are good sources for RWE gathering, but in countries without 
such registries, data collection from clinical practice is still a feasible alternative 
for RWE collection
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what lIfeCyCle maNagemeNt lessoNs CaN we leaRN fRom PD-1 
ImmuNo-oNCology theRaPIes?
Carr DR, Anastasaki E, Chriv E, Bradshaw SE
Market Access Solutions Ltd, London, UK
Objectives: To understand the early lifecycle management strategies of inno-
vative oncology immunotherapies, specifically the PD-1 drugs pembrolizumab 
(Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb), for application 
across disease areas. MethOds: Targeted secondary research using combina-
tions of key words (‘PD-1’, ‘Keytruda’, ‘Opdivo’, ‘FDA’, ‘Pembrolizumab’, ‘Nivolumab’, 
‘Approval’, ‘Immuno-oncology’) identified source literature, which was abstracted 
and analyzed qualitatively. Key themes were discussed in a consensus meeting and 
implications of findings were theorized. Results: Several lifecycle management 
strategies were identified from secondary research, including: indication expansion, 
patient segmentation using biomarkers, and combining with other drug treatments. 
Pembrolizumab and nivolumab - both holders of Breakthrough Therapy status - 
received accelerated approval from the FDA for advanced melanoma in late 2014. 
Nivolumab subsequently received approval for NSCLC in March 2015, while pem-
brolizumab was under FDA Priority Review for the same indication as of June 2015. 
Nivolumab is also under Priority Review in combination with ipilimumab (Yervoy, 
Bristol-Myers Squibb) for melanoma. Both PD-1 therapies are in numerous clinical 
trials for further oncology indications, and pembrolizumab has shown improved 
response rates in patients with a specific genetic biomarker, which is predictive of 
response across a range of cancers. cOnclusiOns: In highly competitive therapeu-
tic areas, manufacturers of innovative products need to consider multiple strategies 
for creating, maintaining, protecting and increasing product value. Demonstration of 
substantial improvements in clinical efficacy over the standard of care in one indi-
cation is not sufficient for ‘success’. Earlier access through the FDA’s Breakthrough 
Therapy designation and accelerated approval program is critical for first-to-market 
entrants. Expansion into both larger and more niche indications offers a comple-
mentary access strategy, while gaining a foothold in combination regimens pro-
vides opportunity for further product differentiation. Similar considerations apply 
to therapies that can treat several indications within a broader disease area.
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Real woRlD evIDeNCe IN oNCology – status Quo IN geRmaNy
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Objectives: Observational studies can be useful to fill in gaps of randomized stud-
ies or when these cannot be conducted. Aim of this study was the assessment of 
available real world evidence (RWE) in oncology and the identification of research 
gaps for Germany. MethOds: A systematic literature search was conducted to 
evaluate the status quo of RWE in the field of oncology. Key words identifying 
health services research in combination with oncology in Germany were used in 
a search performed in the DIMDI (German Institute of Medical Documentation 
and Information) meta-database including all years up to 2015. The selected pub-
lications were classified by type of RWE study and further categorized by cancer 
types. Results: In total, 80 publications were included and stratified by RWE 
approach and cancer type. Nine RWE categories were determined, including cancer 
registries, registry-linked data, health care claims, inpatient and outpatient data, 
and surveys. Most observational studies (56%) assessed oncologic health care by 
conducting surveys, followed by cancer registries (10%) and claims data (9%). Overall, 
32 studies evaluated cancer in general, breast cancer was assessed in 15 studies, 
whereas 4 addressed prostate cancer, with remaining publications addressing other 
cancer types. Most observational studies were published in 2011 (18%). Assessments 
with cancer registries were published as of 2011, whereas there were no studies 
with claims data from 2012-2014. Specific care and treatment of cancer patients, 
including palliative care was considered in 23 publications. Almost all cancer types 
were assessed, except lymphoid and hematopoietic neoplasms. Moreover, claims 
data were hardly used. For surveys, it can be noted that the use increased from 2005 
onwards. cOnclusiOns: The available evidence shows that RWE data in oncology 
has not yet reached its potential to supplement randomized studies. Research gaps 
exist in terms of RWE treatment with new concepts and drugs.
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of PatIeNts wIth BReast CaNCeR
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Objectives: Breast cancer has important economic, psychological and social 
impact for the patients, their families and the health system. Our aim was to 
record the emotional journey of patients with breast cancer during the different 
treatment stages. MethOds: A qualitative study was performed in December 
2014, using a semi-structured interview guide. Participants were recruited through 
a patients’ organization. Women with a diagnosis of primary or secondary breast 
Ca after 2011, residing in Athens who had completed treatment were eligible 
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PatIeNt-CeNtRIC? a ComPaRatIve aNalysIs of 11 systems
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Objectives: To understand how 11 pricing & reimbursement (P&R) processes 
assess the value of innovative medicines to provide sustainable and timely 
patient access. bAckgROund: In November 2014, the UK Minister for Life 
Sciences announced the Innovative Medicines and Medical Technology Review 
to consult various stakeholders on how to improve access to medicines in 
England. MethOds: Eleven processes were analysed focusing on oncology: 
Australia, Belgium, Canada, England, France, Germany, Italy, Netherlands, New 
Zealand, Scotland and Sweden. The decision-making process was split into eight 
steps: regulatory approval, health technology assessment, appraisal, reimburse-
ment decision, price negotiations, decision enforcement, routine access and 
later-stage reassessments. Data collection was based on the Hutton and Allen 
frameworks [Hutton et al. 2006] [Allen et al. 2013]. The analysis relies on a pro-
posed definition of patient-centricity, assuming that value creation for patients 
should determine the reward of other stakeholders [Porter 2010]. It was designed 
to assess how each process delivers value for patients (equity of access, fulfil-
ment of societal needs, fast access to innovation), the healthcare system (eco-
nomic and financial sustainability) and the research-based industry (innovation 
reward). Results: In patient-centric systems, the reimbursement decision tends 
to be solely based on the therapeutic value of the medicine. Cost considerations 
are generally addressed by price negotiations in a second stage. Other processes 
focus more on cost-effectiveness or budget impact (potentially with thresholds), 
which drives the reimbursement decision alongside clinical effectiveness; pricing 
and reimbursement are decided jointly. The English and Scottish processes are the 
only ones that have no price negotiations with manufacturers. cOnclusiOns: 
Patient-centric P&R processes succeed in delivering value to major stakeholders 
by first deciding on the reimbursement status of a new medicine based on its 
value to patients. They then independently negotiate a price with manufacturers 
to ensure economic and financial sustainability for the healthcare system and 
innovation reward for the manufacturer.
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Delays IN DIagNosIs of BReast CaNCeR IN gReeCe: fINDINgs fRom a 
QualItatIve stuDy
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Objectives: Research findings point to the existence of delays in symptom rec-
ognition, diagnosis and treatment of breast cancer. The present study aimed at 
identifying reasons for delay in breast cancer diagnosis in Greece. MethOds: 
A qualitative study was performed in December 2014, using a semi-structured 
interview guide. Recruitment was performed through a patients’ organization. 
Women with a diagnosis of primary or secondary breast Ca after 2011, residing 
in Athens, and who had completed treatment were eligible for the study. The 
interviews were recorded with participants’ written consent and were transcribed 
and content analyzed using a model of patient and provider delay. Results: 23 
women participated. Delays were detected in all intervals of the patient pathway. 
Although most participants performed annual breast cancer screening tests, some 
women had not undergone screening the year previous to their diagnosis due to 
financial and personal reasons. In the majority of cases women were symptomatic, 
however, there were difficulties in appraising symptoms as related to illness. The 
presence of a breast lump is the main symptom that caused non-delayers to seek 
medical attention. Women who had delayed consulting with a physician despite 
having found a breast lump gave the following reasons: misattributing their symp-
tom to benign conditions or breast-feeding, having competing priorities such as 
family and other personal health problems, depression or denial and financial 
barriers to visiting a specialist. The study also identified delays in diagnosis attrib-
uted to the healthcare providers, as in some cases physician(s) did not suspect 
malignancy. cOnclusiOns: Delayed diagnosis of breast cancer among women 
participating in the study is attributed to both patient and provider behavior. Our 
findings indicate that raising awareness and educating both patients and health 
providers is important. However, further research is necessary to identify the 
extent of the problem and confirm these results.
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a PRagmatIC aPPRoaCh to Data souRCe seleCtIoN foR use IN Real-
woRlD evIDeNCe (Rwe) geNeRatIoN
Lie X, Ivanescu C, Nijhuis T
Quintiles Advisory Services, Hoofddorp, The Netherlands
Objectives: Real-world evidence (RWE) can be gathered from various sources, 
including existing registries, claims data or medical records. The challenge is select-
ing the best RWE-source for answering specific research questions. As data sources 
collect different data elements, the best RWE collection approach for gathering 
the necessary data will differ per country. The objective was to test a systematic 
approach for identifying and selecting RWE-sources per indication. MethOds: 
Our approach consisted of two workstreams: assessment of existing RWE-sources 
and inventory of data elements collected in clinical practice. We selected oncol-
ogy as test indication and the European Union as the target area. The first step of 
workstream one is a targeted literature search to identify RWE-sources. Database 
owners were surveyed on their data. A scoring algorithm was developed to prioritize 
RWE-sources on the number and type of relevant data elements. Finally, the most 
promising databases for answering specific research questions were selected based 
on their score and collaboration possibilities. For workstream two, a small sample 
of practicing physicians were interviewed on what data is routinely recorded in 
clinical practice. The results from the two workstreams were combined to analyse 
per country which collection approach is optimal for RWE generation for answering 
